Actively Recruiting
Long-Term Follow-up Study of Allogenic Umbilical Cord-derived Mesenchymal Stem Cell Treatment in Adults With Rotator Cuff Disease
Led by Seoul National University Hospital · Updated on 2026-05-22
21
Participants Needed
1
Research Sites
35 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the long-term safety and effectiveness of allogenic umbilical cord-derived mesenchymal stem cells in patients with rotator cuff disease. The study focuses on monitoring outcomes decades after initial treatment to understand the lasting impact of this therapy. Participants are those who previously received this investigational stem cell treatment in an earlier phase 12a trial. This open-label, single-center study involves a long-term follow-up period extending up to 60 months where patients are observed and evaluated without additional new treatments being administered. During the follow-up, researchers will assess shoulder pain and disability using the Shoulder Pain and Disability Index SPADI score and other measures like the Constant-Murley score and Visual Analog Scale pain during motion. Imaging tests such as MRI will monitor changes in rotator cuff tear size, and any adverse events will be recorded. Participation involves periodic assessments over a five-year period ending in 2032, with safety and efficacy carefully tracked.
CONDITIONS
Brief Title
Long-Term Follow-up Study to Evaluate Long-Term Safety and Efficacy of Allogenic Umbilical Cord-derived Mesenchymal Stem Cell in Patients With Rotator Cuff Disease
Research Team
K
KeeJeong Bae, Principal Investigator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here